Acute graft versus host disease
diseaseOn this page
Also known as acute graft vs. host diseaseacute GVHDfulminant graft versus host diseasegraft versus host disease, acuteGVHD, acute
Summary
Acute graft versus host disease (MONDO:0020546) is a disease and 108 clinical trials. Top therapeutic interventions include methoxsalen, .alpha.1-proteinase inhibitor human, and basiliximab. A subtype of graft versus host disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 108
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acute graft versus host disease |
| Mondo ID | MONDO:0020546 |
| Orphanet | 99920 |
| ICD-10-CM | D89.810 |
| ICD-11 | 83784921 |
| NCIT | C4980 |
| SNOMED CT | 402355000 |
| UMLS | C0856825 |
| MedGen | 208987 |
| GARD | 0006544 |
| MedDRA | 10066260 |
| Is cancer (heuristic) | no |
Also known as: acute graft vs. host disease · acute GVHD · fulminant graft versus host disease · graft versus host disease, acute · GVHD, acute
Disease family
This is a subtype of graft versus host disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › graft versus host disease › acute graft versus host disease
Related subtypes (1): chronic graft versus host disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 108.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 30 |
| Not specified | 27 |
| PHASE1 | 18 |
| PHASE1/PHASE2 | 17 |
| PHASE3 | 11 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02805946 | PHASE4 | COMPLETED | Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections |
| NCT03057054 | PHASE3 | ACTIVE_NOT_RECRUITING | Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant |
| NCT05921305 | PHASE3 | RECRUITING | Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD |
| NCT06294678 | PHASE3 | ACTIVE_NOT_RECRUITING | Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies |
| NCT06294691 | PHASE3 | RECRUITING | Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases |
| NCT07047456 | PHASE3 | RECRUITING | Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT |
| NCT00282503 | PHASE3 | TERMINATED | Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease |
| NCT00726375 | PHASE3 | COMPLETED | The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease |
| NCT02241018 | PHASE2/PHASE3 | UNKNOWN | MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD |
| NCT03371667 | PHASE3 | UNKNOWN | To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids |
| NCT03805789 | PHASE2/PHASE3 | COMPLETED | The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
| NCT04095858 | PHASE3 | TERMINATED | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) |
| NCT05149365 | PHASE3 | COMPLETED | Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation |
| NCT05263999 | PHASE3 | TERMINATED | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) |
| NCT04291261 | PHASE2 | ACTIVE_NOT_RECRUITING | Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease |
| NCT04373057 | PHASE1/PHASE2 | RECRUITING | Prebiotic Galacto-oligosaccharide and Acute GVHD |
| NCT05643638 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD |
| NCT06026371 | PHASE2 | ACTIVE_NOT_RECRUITING | Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation |
| NCT06473909 | PHASE2 | NOT_YET_RECRUITING | Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD |
| NCT06480630 | PHASE2 | NOT_YET_RECRUITING | Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases |
| NCT06880419 | PHASE2 | RECRUITING | Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model |
| NCT06904599 | PHASE2 | RECRUITING | Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment |
| NCT06936566 | PHASE2 | RECRUITING | MAGIC Ruxolitinib for aGVHD |
| NCT06941350 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD |
| NCT07285889 | PHASE1/PHASE2 | RECRUITING | First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) |
| NCT07509749 | PHASE2 | RECRUITING | Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) |
| NCT07572669 | PHASE2 | RECRUITING | Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT00032773 | PHASE1/PHASE2 | TERMINATED | Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD |
| NCT00038792 | PHASE1/PHASE2 | TERMINATED | Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD |
| NCT00350181 | PHASE2 | COMPLETED | Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT |
| NCT00640497 | PHASE1/PHASE2 | WITHDRAWN | Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease |
| NCT00803010 | PHASE2 | COMPLETED | Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation |
| NCT01220297 | PHASE2 | TERMINATED | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT |
| NCT01475162 | PHASE1/PHASE2 | TERMINATED | Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease |
| NCT01530256 | PHASE1/PHASE2 | TERMINATED | Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) |
| NCT01765634 | PHASE2 | UNKNOWN | Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease |
| NCT01903473 | PHASE2 | TERMINATED | Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) |
| NCT02133924 | PHASE2 | COMPLETED | Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease |
| NCT02245412 | PHASE2 | TERMINATED | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease |
| NCT02392780 | PHASE2 | UNKNOWN | Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METHOXSALEN | 4 | 3 |
| .ALPHA.1-PROTEINASE INHIBITOR HUMAN | 4 | 1 |
| BASILIXIMAB | 4 | 1 |
| CANNABIDIOL | 4 | 1 |
| CARMUSTINE | 4 | 1 |
| CHOLESTYRAMINE | 4 | 1 |
| ETANERCEPT | 4 | 1 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| LEFLUNOMIDE | 4 | 1 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | 4 | 1 |
| NATALIZUMAB | 4 | 1 |
| PENTOSTATIN | 4 | 1 |
| POSACONAZOLE | 4 | 1 |
| ITOLIZUMAB | 3 | 3 |
| ITACITINIB | 3 | 2 |
| CD24FC | 3 | 1 |
| CLAZAKIZUMAB | 3 | 1 |
| DEFIBROTIDE | 3 | 1 |
| MALTODEXTRIN | 3 | 1 |
| FLIZASERTIB | 2 | 1 |
| LETOLIZUMAB | 2 | 1 |
| NEIHULIZUMAB | 2 | 1 |
| OLENDALIZUMAB | 2 | 1 |
| EFMARODOCOKIN ALFA | 1 | 1 |
| PLX-51107 | 1 | 1 |
| CHEMBL5081624 | 0 | 1 |
| CHEMBL1233255 | 0 | 1 |